Zhang Ziyi celebrates her stepdaughter’s birthday

November 25 is the 14th birthday of “little apple”, the daughter of Wang Feng and his ex-wife. The 14-year-old girl has lost her childishness and become a big girl. As a father, Wang Feng is full of feelings and regrets about the wonder of the years. Wang Feng has published a long article about what he wants to say to his daughter, and let his daughter not think of him as nagging, as if he saw a kind old father’s advice to her daughter.
Wang Feng shows some growing pictures of the little apple. From the little apple with red scarf and childishness to the big girl today, it can be seen that Wang Feng is a very careful father who carefully keeps the little apple of her daughter. The little apple in childhood is really super cute, and the round face is really like her name, like a “little apple”.
During the tooth changing period of little apple, Zhang Ziyi integrated into her life. The little apple in the picture is 8 years old, holding Kitty Cat cake in her hand, snuggling up in the arms of her father and Zhang Ziyi’s mother. This is Zhang Ziyi’s first birthday with little apple.
Then, new members of the family “wake up”, Zhang Ziyi did not wake up because of the arrival of neglect of small apple, mother and daughter get along very well. Often can see Zhang Ziyi takes the small apple to go shopping or play the picture.
Wang Feng, Zhang Ziyi, celebrated Apple’s 11th birthday at home.
Now, Apple has cut off the long straight hair that is fast to his waist, replaced it with a ragged hair over his shoulder, which is more mature and more beautiful.
Small apple in the “Star II” is definitely a high beauty value.
Zhang Ziyi follows Wang Feng’s blessing to Xiao apple and calls himself “mother”. It can be seen that although the two are not related by blood, the intimacy between mother and daughter is a little bit more. Zhang Ziyi, the stepmother, should be absolutely qualified.
Zhang Ziyi attached a photo of herself and the little apple. The little apple tied the head of the ball, the cheeks faded away from the baby’s fat, and the water became more and more beautiful. The mother and daughter were very close together. Now Zhang Ziyi is in the late stage of pregnancy. She is wearing a white sweater, and there is a handful of roses in front of her, which cleverly blocked the pregnant belly.
Compared with the appearance of traveling with her daughter some time ago, Zhang Ziyi’s face seems to be a little puffy at the end of her pregnancy. Her chin is not so tight. As an old pregnant mother, it’s really not easy. Once again, I wish her baby a safe birth and happy birthday of little apple.

New drugs for Alzheimer’s disease

A new drug for Alzheimer’s disease developed by Ocean University of China, Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences and Shanghai Green Valley Pharmaceutical Co., Ltd. has been approved by the State Drug Administration, which can be used for mild to moderate Alzheimer’s disease and improve cognitive function of patients, the reporter learned from Shanghai Institute of medicine of Chinese Academy of Sciences on Tuesday. The drug is the first time in the world and will provide new treatment options for patients.
Geng Meiyu, a researcher from Shanghai Institute of medicine, Chinese Academy of Sciences, led the team to develop the original new drug named “nine phase one” (mannose sodium, code name gv-971) for 22 years, which was successfully developed under the continuous efforts of China Ocean University, Shanghai Institute of medicine, Chinese Academy of Sciences and Shanghai Green Valley pharmaceutical.
Alzheimer’s disease is commonly known as Alzheimer’s disease, once the disease, people’s memory, thinking and judgment ability will be like the “eraser” in the mind slowly wiped away. According to the international Alzheimer’s Association, there are about 48 million patients in the world, and one new case will be added every three seconds. With the aging of the population, the harm of Alzheimer’s disease is more and more obvious.
Geng Meiyu (third from left), the main inventor of the new drug and researcher of Shanghai Institute of medicine, Chinese Academy of Sciences, and the research and development team are discussing their work (photo taken on January 2, 2019) Xinhua social development (picture provided by Shanghai Institute of medicine, Chinese Academy of Sciences)
There are only a few drugs for clinical treatment of Alzheimer’s disease in the world. Over the past 20 years, major pharmaceutical companies have invested heavily in the research and development of new drugs, most of which have failed. No new drugs have been launched in this field for 17 years.
It is understood that 1199 subjects participated in the phase 1, phase 2 and phase 3 clinical trials. Among them, the third phase of clinical practice was organized by the mental health center affiliated to the Medical College of Shanghai Jiaotong University and Beijing Union Medical College, and carried out in 34 third-class first-class hospitals across the country, with 818 subjects’ medication observation completed. The whole clinical trial is managed by AI kunwei, a global famous outsourcing service organization for new drug research and development.
A new drug for Alzheimer’s disease, “nine phase one” (ganlute sodium) (photo taken on November 2, 2019) Xinhua social development (picture provided by Shanghai Institute of medicine, Chinese Academy of Sciences)
The results of a 36 week three-phase clinical study showed that “nine phases one” can significantly improve cognitive impairment in patients with mild and moderate Alzheimer’s disease. Compared with the placebo group, the main efficacy index cognitive function improved significantly, cognitive function scale score improved by 2.54 points (P < 0.0001). The incidence of adverse events was similar to that of placebo group.
According to Geng Meiyu, the preclinical mechanism of action shows that “nine phases one” can improve cognitive dysfunction by reshaping the balance of intestinal flora, inhibiting the abnormal increase of specific metabolites of intestinal flora, reducing peripheral and central inflammation, reducing β – amyloid protein deposition and tau protein hyperphosphorylation. The unique mechanism of targeting brain gut axis provides an important scientific basis for deep understanding of the clinical effect of “nine phases one”.